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The purpose of this study was to establish the relative contribution of tumour stage, node stage, p53 gene status, p53
expression, and bcl-2 protein expression to tumour response to platin-ﬂuorouracil chemotherapy in 141 patients with
squamous-cell carcinomas of the head and neck. Tumour response was measured at the primary site after three cycles of
chemotherapy. Exons 2–10 and the coding part of exon 11 were sequenced on both strands. Bcl-2 or p53 expression was
detected by immunohistochemistry. Predictor variables of objective response (reduction of at least 50% of tumour size) were
tested in univariate and multivariate analyses. P53 mutations were found in 52 patients (37%). Tumour cells expressed p53 in
84 cases (59%) and bcl-2 in 25 cases (18%). T1 or T2 stage (adjusted odds ratio, 3.3; 95% conﬁdence intervall 1.3–8.7;
P=0.01), N0 node stage (adjusted odds ratio, 2.7; 95% conﬁdence interval 1.1–6.4; P=0.03), p53 wild-type gene (adjusted
odds ratio, 4 .0; 95% conﬁdence interval 1.7–9.5; P=0.002), and bcl-2 protein expression (adjusted odds ratio, 20; 95%
conﬁdence interval 2.3–170; P=0.006), were positively associated with tumour response. P53 protein expression was not
predictive of response. In conclusion, tumour stage, node stage, p53 gene status, and bcl-2 expression are independent
predictors of tumour response to platin-ﬂuorouracil in patients with squamous-cell carcinomas of the head and neck.
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To establish factors linked to responses to radiotherapy or
chemotherapy is currently a major goal of basic and translational
research. It may help select patients for speciﬁc treatment and
point to new targets for drugs. P53 protein is the product of one
of the most frequently mutated tumour suppressor gene in cancer
and also an important determinant of tumour cell sensitivity to
DNA alterations including those induced by genotoxic drugs (Lowe
and Lin, 2000; Lowe et al, 1993). P53 mutation has been linked to
poor responses to treatment in a variety of tumour types (Aas et al,
1996; Bergh et al, 1995; Chresta et al, 1996; Ichikawa et al, 1997).
Among squamous-cell carcinomas of the head and neck (SCCHN),
tumours with wild-type p53 are twice as likely to respond to radio-
therapy as tumours with p53 mutation (Koch et al, 1996).
Esophageal carcinomas with p53 mutations are also poor respon-
ders to chemoradiotherapy (Ribeiro et al, 1998). In a previous
study we were able to show that wild-type p53 gene status is a
strong predictor of tumour response to platin-ﬂuorouracil
chemotherapy used in induction for treatment of loco-regionally
advanced SCCHN (Temam et al, 2000). This result has been
conﬁrmed by others (Cabelguenne et al, 2000).
Although a lack of p53 mutation was the strongest predictor of
tumour response in our work, we were aware that many cases with
p53 mutations in our previous series were also responsive to
chemotherapy. This suggested that response to chemotherapy
may occur by ways other than p53-dependent drug-induced
tumour cell apoptosis. Fundamental research has shown that apop-
tosis may be induced by both p53-dependent and p53-independent
pathways (Clarke et al, 1993). The issue in such context – cell
death or survival – seems to depend on the cellular levels of
several pro- or anti- apoptotic molecules, many of which belong
to a family of bcl-2 homologous proteins (Oltvai et al, 1993;
Shimizu et al, 1999). Bcl-2 itself is an antiapoptotic protein, whose
forced expression in cells generally protects against apoptosis
(Tsujimoto et al, 1985). However, few studies at present have
demonstrated that bcl-2 expression in tumour cells are linked to
resistance to treatment except for lymphomas (Hermine et al,
1996; Schmitt et al, 2000). Actually, bcl-2 expression has been asso-
ciated with a good response to treatment in some cancers
(Fontanini et al, 1995; Joensuu et al, 1994; Pezzella et al, 1993).
Bcl-2 expression correlated with favourable outcome in SCCHN
treated by radiotherapy (Wilson et al, 1996) and better local regio-
nal control in patients treated by concurrent radiochemotherapy
(Homma et al, 1999). Patients whose tumours expressed bcl-2,
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a high likelihood of cure with aggressive combined modality ther-
apy (Pena et al, 1999).
The present work determines the relative contribution of p53
gene status, bcl-2 expression, tumour stage, and node stage to
the tumour response to platin-ﬂuorouracil chemotherapy in a
retrospective series of 141 consecutive cases of SCCHN.
PATIENTS AND METHODS
Patients
From September 1992 to December 1995, 276 cases of SCCHN
(excluding nasopharyngeal tumours) were newly diagnosed in the
Service d’Oto-Rhino-Laryngologie et de Chirurgie de la Face et
du Cou (Ho ˆpital Tenon, Paris, France). All 141 patients treated
by induction chemotherapy during this period were consecutively
included. Of these 141 cases, 107 patients presented with stage
III or stage IV SCCHN and have been previously studied (Temam
et al, 2000). The present study includes 34 additional patients with
stage II SCCHN. Diagnosis, chemotherapy, response evaluation,
radiotherapy, and surgery were performed at the same institution.
The study was approved by the ethical committee.
Treatment plan
For patients with stage III or stage IV tumours the treatment plan
consisted of chemotherapy according to a modiﬁed Al Sarraf
protocol followed by response evaluation at the primary tumour
site, then local therapy which was either radiotherapy alone or
salvage surgery and radiotherapy.
For patients with stage II tumours the treatment plan consisted
of chemotherapy followed by surgery. All patients had three
planned cycles of chemotherapy. Each cycle consisted of cisplatin
(20 mg m
72 per day) administered as a continuous intravenous
24-h infusion, simultaneously with a continuous infusion of ﬂu-
orouracil (1000 mg m
72 per day) for 4 days. Chemotherapy was
withdrawn in cases of tumour progression or in patients who
did not respond after two cycles.
The ﬁnal response was estimated from the last clinical and endo-
scopic evaluation, which was performed under general anaesthesia
2 weeks after the last cycle. Tumour shrinkage was evaluated as the
decrease in the sum of the product of the largest perpendicular
diameters of the measurable lesions at the primary tumour site.
An objective response was deﬁned by a decrease of at least 50%
of initial tumour size.
Sequencing of the p53 gene
DNA samples were obtained from the formalin-ﬁxed parafﬁn-
embedded biopsy specimens, which have been used for diagnosis.
In cases with multiple biopsy specimens of the same tumour,
one specimen was selected on the basis of more abundant tumour
tissue or randomly chosen. Tumour tissue was microdissected with
surgical blades under a binocular lens at a 650 magniﬁcation, and
digested in 100 ml buffer containing 200 mgm l
71 proteinase K
overnight at 378C.
The processing of slides, the preparation and storage of DNA
samples, and the polymerase chain reactions (PCR) were
performed in other rooms than those in which PCR products were
manipulated.
Each exon was separately ampliﬁed except for exon 2 and 3
which were ampliﬁed together. Each primer pair included splice
junctions. The PCR procedure and primers for exons 5–9 were
as described elsewhere (Hsu et al, 1991). The same PCR conditions
were used for exons 2–4, exon 10, and the coding part of exon 11,
with speciﬁcally designed primer pairs as described (Temam et al,
2000). The column-puriﬁed PCR products were sequenced using
fresh internal primers and ﬂuorescent dye–labelled dideoxynucleo-
tides (Dye-Terminator sequencing kit; Perkin Elmer, Norwalk, CT,
USA). Fluorograms collected with a DNA sequencer (Applied
Biosystems, Foster City, CA, USA) were analysed using the
Sequence Navigator software (Applied Biosystems) to identify
mutations by comparison with ﬂuorograms from wild-type
samples. Mutations were identiﬁed and conﬁrmed in both strands
in two independent ampliﬁcation and sequencing experiments.
Neutral mutations and known polymorphisms were not counted
as mutations.
Immunohistochemistry
Immunohistochemistry was performed in an automated processor
(Techmate 500; Dako, Carpenteria, CA, USA) following standard
procedures. The monoclonal antibody DO7 (Novocastra, Newcas-
tle upon Tyne, UK) reacts strongly in formalin-ﬁxed material with
an antigenic determinant from the amino-terminal region of both
the wild-type and mutant forms of p53 protein (Anwar et al,
1993). The monoclonal antibody clone 124 (Dako, Carpenteria,
CA, USA) reacts with bcl-2 cytoplasmic protein (Pezzella et al,
1990).
To enhance the signal, deparafﬁnised sections were microwaved
before being incubated with the primary antibody (p53, 1:200,
overnight at 48C; bcl-2, 1:50, 1 h at room temperature). Sections
were incubated with a biotinylated goat antimouse immunoglobu-
lin at a 1/600 dilution, then reacted with peroxydase-labelled
streptavidin at a 1/800 dilution. The slides were developed with a
solution containing diaminobenzidine tetrahydrochloride at a ﬁnal
concentration of 0.2 mg ml
71 and 0.005% H2 O2 in Tris-buffered
saline, then counterstained with Harris haematoxylin.
Specimens were blindly and independently evaluated for p53
and bcl-2 staining by two observers (S Temam and P Fouret).
Percentage of positive cells were recorded. Staining in less than
5% of tumour cells was scored as negative. All series for p53
immunostaining included immunoreactive breast carcinoma speci-
mens as p53-positive external controls. Bcl-2 reactivity was
controlled with adjacent lymphocytes. Negative controls included
replacement of the monoclonal antibody with a mouse myeloma
antibody of the same subclass.
Statistical analysis
Signiﬁcance testing for discrete variables was performed with the
chi 2 test or the Fisher’s exact test when appropriate.
Predictor variables with a P value less than 0.05 in the univariate
analyses were submitted to multivariate analysis with response to
chemotherapy as the dependant variable. Statistica software (Stat-
Soft Inc., Tulsa, OK, USA) was used to develop the multivariate
logistic-regression models. The relative risk to respond to
chemotherapy was estimated by adjusted odds ratios with 95%
conﬁdence intervals.
All reported P values are two-sided. A value of 0.05 was chosen
to indicate statistical signiﬁcance.
RESULTS
P53 mutations
Forty mutations (37%) had been found in 107 cases of stage III or
stage IV SCCHN. The analysis of 34 additional cases with stage II
SCCHN yielded 12 mutations (35%), a prevalence which was not
statistically different from the late stage series. These mutations
are shown in Table 1. There was a perfect concordance between
the type of mutation and p53 expression as every missense muta-
tion expressed the protein, while the two stop mutations did not.
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deletions, and the remaining 21 (39%) were predicted to interrupt
the reading frame (nine stop mutations, six splice junction muta-
tions, and six frameshift deletion or insertion mutations). A
majority of mutations (83%) were localised in exons 5–9, while
eight mutations were found in exon 4, and one in exon 10.
Immunohistochemical analysis of p53 and bcl-2 protein
expression (photographic pictures available on request)
P53 staining of tumour cells was observed in 84 patients (59%).
The percentage of positive cells varied from 5–95% (median 50%).
Bcl-2 staining of tumour cells was observed in 25 patients
(18%). The percentage of positive tumour cells varied from 5–
90% with 12 cases having 10% or more positive cells (median 5%).
Characteristics of patients
Most patients were male (89%) and smokers (95%). The median
age was 59 years (range, 29–79 years). Fifty-six patients (40%)
presented with T1 or T2 tumour stage, and 81 patients (57%)
presented with N0 node stage. Tumour localisation was laryngeal
in 59 cases (42%), and involved the oral cavity in seven cases
(5%), the oropharynx in 52 cases (37%), and the hypopharynx
in 23 cases (16%).
For the 34 patients with stage II SCCHN, tumour site was laryn-
geal in 19 cases, and involved the oral cavity in three cases, the
oropharynx in 11 cases, and the hypopharynx in only one case.
Patients characteristics were analysed according to p53 gene
status (Table 2). There was no difference between patients with
p53 wild-type and those with p53 mutation. The p53 mutation rate
was lower for tumours of the oral cavity (one out of seven cases;
14%) and of the hypopharynx (ﬁve out of 23 cases; 22%) than
for tumours of the larynx (24 out of 59 cases; 41%) and the
oropharynx (22 out of 52 cases; 42%), although all differences were
not signiﬁcant (P40.11 for all comparisons).
Similarly, there was no difference between patients whether or
not they expressed bcl-2 protein (Table 2).
Univariate analyses of tumour response
Two patients with late stage disease could not be evaluated for their
tumour response and were therefore excluded from the analyses.
Among 139 patients, 99 (71%) had an objective response, and
40 (29%) did not respond. All but one patient (97%) with clinical
stage II responded to chemotherapy, which was signiﬁcantly higher
than the proportion of responders among patients with clinical
stage III or stage IV (66 out of 105, or 63%; P=0.0001; Table 3).
T1 or T2 tumour stage was signiﬁcantly associated with response
to chemotherapy as 48 out of 56 patients (86%) with early tumour
stage were responders as compared with only 51 out of 83 patients
(67%) with T3 or T4 tumour stage (P=0.002). Among 81 node
negative patients there were 64 responders (79%), while 35 out
of 58 patients (60%) with N1–N3 node stage responded to
chemotherapy (P=0.02).
P53 protein expression was not predictive of tumour response
(P=0.12). However, 71 out of 88 patients (81%) with wild-type
p53 responded to chemotherapy in contrast to only 28 out of 51
patients (55%) with p53 mutation (P=0.001).
Twenty-four out of 25 patients (96%) expressing antiapoptotic
bcl-2 protein (5% or more positive bcl-2 positive tumour cells)
responded to chemotherapy (Table 4). Among the remaining 114
patients whose tumour cells did not express bcl-2 protein, 75
(66%) were responders (P=0.001).
Twelve out of 12 patients (100%) expressing bcl-2 protein in at
least 10% of tumour cells were responders. Among the remaining
127 whose tumour contained less than 10% bcl-2 positive cells, 87
(59%) were responders (P=0.02).
Interestingly, among 51 patients with p53 mutation 10 cases
(20%) expressed bcl-2 protein. These 10 bcl-2 positive cases
responded to chemotherapy despite p53 mutation. Six out of these
10 cases presented with T3 or T4 stage. In contrast among the
remaining 41 cases which also had p53 mutation, but did not
express bcl-2 protein, only 18 cases (44%) were responders
(P=0.001).
Multivariate analyses of tumour response
Univariate analyses had identiﬁed tumour stage, node stage, p53
gene status, and bcl-2 protein expression as signiﬁcant predictors
of tumour response. These covariates were entered in a multivari-
ate model with tumour response as the dependant variable.
Tumour stage, node stage, p53 wild-type gene status and bcl-2
protein expression were shown to be positively associated with
tumour response (Table 5).
P53 wild-type gene status (adjusted odds ratio, 4.0; 95% conﬁ-
dence interval 1.7–9.5; P=0.002) was the strongest predictor of
tumour response.
The correlation of bcl-2 protein expression with response was
also strong, although the unique bcl-2 positive case who did not
respond to chemotherapy was responsible for a very high and
imprecise 95% conﬁdence interval upper limit (95% conﬁdence
interval 2.3–170).
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Table 1 P53 mutations in 12 patients with early stage squamous cell carcinoma of the head and neck
Exon Codon Sequence Amino acid P53 expression Response
4 36 CCG-CGG P-R Expression No response
4 120 AAG-GAG K-E Expression Objective response
5 136 CAA-TAA Q-* No expression Objective response
5 175 CGC-CAC R-H Expression Objective response
5 179 CAT-TAT H-Y Expression Objective response
6 209 AGA-TGA R-* No expression Objective response
6 213 CGA-CTA R-L Expression Objective response
6 220 TAT-TGT Y-C Expression Objective response
7 244 GGC-TGC G-C Expression Objective response
7 245 GGC-AGC G-S Expression Objective response
7 245 GGC-TGC G-C Expression Objective response
8 272 CGT-TGT R-C Expression Objective response
Exons 2–10 and the coding part of exon 11 were sequenced on both strands. Mutations were conﬁrmed in independent experiments.
P53 expression was detected by immunohistochemistry. The tumour response was measured at the primary site. Objective response:
decrease of at least 50% of tumour size.
P53 and bcl-2 predict tumour response to chemotherapy
P Fouret et al
1392
British Journal of Cancer (2002) 87(12), 1390–1395 ã 2002 Cancer Research UKTo test the robustness of these data, multivariate analysis was
also performed using the 10% cutoff for bcl-2 protein expression.
Tumour stage (adjusted odds ratio, 3.3; 95% conﬁdence interval
1.3–8.6; P=0.01), node stage (adjusted odds ratio, 2.8; 95% conﬁ-
dence interval 1.2–6.5; P=0.02), p53 wild-type gene status
(adjusted odds ratio, 3.9; 95% conﬁdence interval 1.6–9.0;
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Table 2 Characteristics of 141 patients and tumours according to p53 gene status or blc-2 expression
p53 wild-type p53 mutation bcl-2 expression No bcl-2 expression
Variable (n=89) (n=52) P (n=25) (n=116) P
Age 0.24 0.34
459 years 45 21 14 53
W 59 years 44 31 11 63
Sex 0.54 0.54
Male 80 45 23 102
Female 9 7 2 14
Smoking status 0.26 0.80
Smoker 83 51 24 110
Non-smoker 6 1 1 6
Clinical stage 0.97 0.47
II 22 12 7 27
III 21 13 5 29
IV 46 27 13 60
Tumour stage 0.19 0.67
T1 or T2 39 17 11 45
T3 or T4 50 35 14 71
Node stage 0.80 0.48
N0 52 29 13 68
N1-N3 37 23 12 48
Localisation 0.43 0.49
Laryngeal 35 24 12 47
Other 54 28 13 69
Bcl-2 expression was detected by immunohistochemistry. Tumour and node stages according to the International Union against Cancer
(1992).
Table 3 Univariate analyses of tumour response to platin-ﬂuorouracil
chemotherapy
Non responder Responder
Variable (n=40) (n=99) Odds ratio P
Age 0.16
459 years 15 50
W 59 years 25 49
Sex 0.56
Male 37 86
Female 3 13
Smoking status 0.41
Smoker 37 95
Non-smoker 3 4
Clinical stage 20 0.0001
II 1 33
III or IV 39 66
Tumour stage 3.7 0.002
T1 or T2 8 48
T3 or T4 32 51
Node stage 2.5 0.02
N0 17 64
N1-N3 23 35
Localisation 0.52
Laryngeal 15 43
Other 25 56
P53 expression 0.12
Expression 28 55
No expression 12 44
P53 gene status 3.4 0.001
Wild-type 17 71
Mutation 23 28
Bcl-2 expression 12 0.003
Expression 1 24
No expression 39 75
Responder: reduction of at least 50% of tumour size.
Table 4 Objective response according to the percentage of bcl-2
protein positive tumour cells
Percentage of bcl-2 positive tumour cells
0–4% 5–9% 10–49% 50–89% 90–100%
Variable (n=114) (n=13) (n=9) (n=2) (n=1)
Objective response
Yes 75 12 9 2 1
No 39 1 0 0 0
Table 5 Multivariate analyses of tumour response to platin-ﬂuoroucil
chemotherapy
Variable Odds ratio 95% Conﬁdence interval P
Tumour stage T1 or T2 3.3 1.3–8.7 0.01
T3 or T4 1
Node stage N0 2.7 1.1–6.4 0.03
N1-N3 1
P53 gene status Wild-type 4.0 1.7–9.5 0.002
Mutation 1
Bcl-2 expression Expression 20 2.3–170 0.006
No expression 1
Variables shown to be signiﬁcantly associated with tumour response in univariate
analyses were submitted as covariates to logistic-regression analysis. Odds ratio:
adjusted odds ratios. Bcl-2 expression: bcl-2 protein expression in at least 5% of
tumour cells.
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cells (adjusted odds ratio, 26; 95% conﬁdence interval 1.2–559;
P=0.04) were also positively associated with response in this model.
DISCUSSION
This study is an expansion of our previous study (Temam et al,
2000), but includes 34 new patients with earlier disease. The addi-
tional patients do correct for some deﬁciencies in our previous
analysis of the relationships of clinical parameters as well as p53
gene status to objective response to chemotherapy. In addition,
we provide immunostaining data which suggest that bcl-2 protein
expression in tumour cells is a useful biological marker for predict-
ing tumour response to induction therapy.
The 34 new patients were treated by chemotherapy and evalu-
ated for tumour response in the same manner as patients with
late disease. All coding exons of p53 gene were sequenced, revealing
12 additionnal mutations. This study indicates that the prevalence
of mutations does not increase with clinical stage. Tumour and
node stages were marginally predictive of tumour response in
our previous study. The current study clearly indicates that tumour
and node stages are clearly signiﬁcant predictors of tumour
response, although the correlation with response appears to be
stronger for tumour stage than node stage. These clinical para-
meters are known predictors of tumour response in the
literature. Our previous study indicated that p53 mutations are
associated with poor tumour response to induction chemotherapy
in patients with advanced disease. A similar conclusion has been
reached by Cabelguenne et al (2000) in a prospective study. In
the current study, p53 gene status, tumour stage, and node stage
predict tumour response by multivariate analysis. Here, the contri-
bution of clinical parameters are correctly evaluated, which
strengthen the valididity of our conclusion. Strikingly, p53 gene
status remains the strongest predictor of response.
The role of p53 protein in apoptosis suggests that mechanisms
leading to apoptosis are important determinants of tumour
response. As a ﬁrst step to explore sensitivity to apoptosis in tissue
samples, we assayed bcl-2 protein expression by immunostaining
tumour cells with a monoclonal antibody, which is widely used
and gives very consistent results in parafﬁn-embedded specimens
(Pezzella et al, 1990). We did all the appropriate controls. The
proportion of bcl-2 positive cases (17%) is close to those reported
in other studies (Gasparini et al, 1995; Gallo et al, 1996; Wilson et
al, 1996; Pena et al, 1999). The multivariate analysis shows a strong
association of bcl-2 positivity (5% or more immunoreactive
tumour cells) to tumour response, which is independent of tumour
stage, node stage, and p53 gene status. Our scoring of bcl-2 posi-
tivity is admittedly subjective, but the predictive value of bcl-2
protein expression is also found with another cut-off (10% or
more positive tumour cells). Our analysis also reveals that bcl-2
positivity predicts a good response to chemotherapy even in cases
with p53 mutations. Among these cases, several presented with T3
or T4 stage, suggesting that this effect is not related to tumour
stage, although we could not ﬁt a multivariate model to the small
number of observations. This suggests that bcl-2 immunoreactivity
points to cases where a p53-independent response may predomi-
nate over tumour cell failure to achieve p53-dependent apoptosis.
The clinical signiﬁcance of bcl-2 protein expression in SCCHN
is not clearly established. Gallo et al (1996) reported that bcl-2
expression is closely associated with a high risk of recurrence
and poor survival in stage I and II SCCHN patients. In contrast,
Gasparini et al (1995) reported that bcl-2 SCCHN are highly
responsive to concurrent chemoradiotherapy in univariate analysis.
Homma et al (1999) also reported that in patients treated with
concurrent chemoradiotherapy bcl-2 positivity predicts better
locoregional control, based on a multivariate analysis. In a previous
study, Wilson et al (1996) reported that bcl-2 expression correlates
with favourable outcome in SCCHN treated by radiotherapy. The
study of Pena et al (1999) indicated that bcl-2 positivity, even with
locoregionally advanced disease, has a high likelihood of cure with
aggressive combined modality therapy. Together, these studies
suggest that bcl-2 protein expression in SCCHN associates with
improved therapeutic response to genotoxic treatments. Our study
is the ﬁrst to indicate that bcl-2 positivity correlates with a better
tumour response to induction chemotherapy.
Bcl-2 family proteins play pivotal roles in controlling cell death
(Oltvai et al, 1993; Shimizu et al, 1999). Bcl-2 protein itself belongs
to the group of prosurvival members. Therefore, it seems paradox-
ical that tumours expressing bcl-2 protein demonstrate an improved
therapeutic response. The association of bcl-2 expression with better
outcome has been reported in lung (Pezzella et al, 1993; Fontanini et
al, 1995), breast (Joensuu et al, 1994), colon (Baretton et al, 1996)
and ovarian carcinomas (Diebold et al, 1996). Expression of bcl-2
protein is common in undifferentiated carcinomas of the nasophar-
yngeal tract (Lu et al, 1993), which are nevertheless very sensitive to
radiotherapy. In contrast, bcl-2 expression in lymphomas is asso-
ciated with a poor response to therapy (Hermine et al, 1996). Bcl-
2 positive lymphomas are characterised by very high levels of bcl-
2 protein in 100% of tumour cells, which is related to speciﬁc trans-
locations (Tsujimoto et al, 1985). It seems very likely that bcl-2
overexpression in lymphoma cells is the cause of tumour resistance
to treatment (Schmitt et al, 2000). The context appears very differ-
ent in epithelial malignancies, where bcl-2 protein expression is
usually restricted to a proportion of tumour cells. In epithelial
tumours the mechanisms leading to bcl-2 protein expression are
certainly different from lymphomas. It is possible that bcl-2 protein
expression in some epithelial malignant cells is actually a reactive
change to alterations of other bcl-2 family members or other regu-
lators of apoptosis. Fundamental research strongly suggests that
tumour cell sensitivity to genotoxic damage is induced by oncogenic
changes which promote apoptosis (Lowe and Lin, 2000). Bcl-2
protein expression in epithelial malignancies is probably a reactive
and reversible cellular mechanism to suppress pro-apoptotic onco-
genic changes, which may be stronger in some tumours.
The data from this retrospective analysis support the conclusion
that bcl-2 protein expression may be a clinically relevant determi-
nant of response of SCCHN to treatment. If dependence on bcl-2
protein is associated with greater chimiosensitivity, even in
tumours with p53 mutations, the molecular alterations related to
bcl-2 positivity may have important implications on the rational
approach to treatment of SCCHN.
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